Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Chern Siang Lee"'
Autor:
Sergio Cogliatti, Chern Siang Lee, Margaret Ashton-Key, Stephanie Rondeau, Shu-Fang Hsu Schmitz, Peter Johnson, Mark S. Cragg, Michele Ghielmini
Publikováno v:
British Journal of Haematology. 168:145-148
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0567aa1181572e56804a85b611402410
https://doi.org/10.1111/bjh.13071
https://doi.org/10.1111/bjh.13071
Publikováno v:
Clinical Teacher. Jun2008, Vol. 5 Issue 2, p119-123. 5p. 3 Color Photographs, 2 Charts.
Publikováno v:
British Journal of Clinical Pharmacology. 76:233-247
Cancers must evade or suppress the immune system in order to develop. Better understanding of the molecular regulation governing tumour detection and effective activation of the immune system (so called immune regulatory checkpoints) has provided new
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f1d117262899f7a1136b59ce7bd40053
https://doi.org/10.1111/bcp.12164
https://doi.org/10.1111/bcp.12164
Publikováno v:
The Clinical Teacher. 5:119-123
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::873e1144965a789632970b2efa19552a
https://doi.org/10.1111/j.1743-498x.2008.00211.x
https://doi.org/10.1111/j.1743-498x.2008.00211.x
Autor:
Andrew Davies, Chern Siang Lee
Publikováno v:
Challenging Concepts in Oncology
Follicular lymphoma is the commonest subtype of indolent non-Hodgkin’s lymphoma (NHL), with a steady rise in incidence over the last 40 years. It has a long clinical course, characterized by a progressing and regressing pattern in response to treat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::53cdaa72e900c173d0fb92f4594c9736
https://doi.org/10.1093/med/9780199688883.003.0015
https://doi.org/10.1093/med/9780199688883.003.0015
Autor:
George Papaxoinis, Ciara O’Brien, Sophia Callaghan, Richard Adams, Timothy Iveson, Saifee Mullamitha, James Bennett, Chern Siang Lee, Rhiannon Mai Evans
Publikováno v:
Journal of Clinical Oncology. 35:e15043-e15043
e15043 Background: Trifluridine/tipiracil (TAS-102), an oral combination of a nucleoside analogue and thymidine phosphorylase inhibitor, showed significant survival benefit in the RECOURSE study. We assessed TAS-102 clinical activity in an unselected
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::80e5923251361838d1cd21355791403d
https://doi.org/10.1200/jco.2017.35.15_suppl.e15043
https://doi.org/10.1200/jco.2017.35.15_suppl.e15043
Autor:
Chern Siang Lee, Peter Johnson, Sergio Cogliatti, Mark S. Cragg, Hsu-Fang Schmitz, Susanne Crowe, Margaret Ashton-Key, Michele Ghielmini
Publikováno v:
The Lancet. 381:S63
Background FcγRIIB promotes rituximab internalisation on various B-cell targets, including in follicular lymphoma, which may lead to reduced efficacy. We analysed diagnostic tumour samples from the SAKK 35/98 trial, which has follow-up data of nearl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ac9a8500401fa652460ad8c6fe75236b
https://doi.org/10.1016/s0140-6736(13)60503-6
https://doi.org/10.1016/s0140-6736(13)60503-6
Autor:
Margaret Ashton-Key, Mark S. Cragg, Shu-Fang Hsu Schmitz, Susanne Crowe, Peter Johnson, Sergio Cogliatti, Michele Ghielmini, Chern Siang Lee
Publikováno v:
Blood. 120:2747-2747
Abstract 2747 Background: Single-agent immunotherapy with rituximab is a viable treatment option for low risk FL, with limited toxicity and a long duration of response in some patient subsets. We have previously shown that high expression of FcγRIIB
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6620b1cc7e1118d2b73275413953414a
https://doi.org/10.1182/blood.v120.21.2747.2747
https://doi.org/10.1182/blood.v120.21.2747.2747